Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 34,600 shares, a decrease of 23.3% from the July 15th total of 45,100 shares. Based on an average daily trading volume, of 29,000 shares, the short-interest ratio is presently 1.2 days.
Bioasis Technologies Stock Performance
BIOAF stock opened at $0.12 on Monday. The company's 50 day moving average price is $0.13 and its 200 day moving average price is $0.17. Bioasis Technologies has a fifty-two week low of $0.10 and a fifty-two week high of $0.28. The firm has a market capitalization of $9.50 million, a price-to-earnings ratio of -2.99 and a beta of 0.19.
Get Bioasis Technologies alerts:Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last announced its quarterly earnings results on Tuesday, June 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. Equities analysts forecast that Bioasis Technologies will post -0.05 EPS for the current fiscal year.
Bioasis Technologies Company Profile
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
